Title: | Nanoparticulation of BCG-CWS for application to bladder cancer therapy |
Authors: | Nakamura, Takashi Browse this author |
Fukiage, Masafumi Browse this author |
Higuchi, Megumi Browse this author |
Nakaya, Akihiro Browse this author →KAKEN DB |
Yano, Ikuya Browse this author →KAKEN DB |
Miyazaki, Jun Browse this author →KAKEN DB |
Nishiyama, Hiroyuki Browse this author →KAKEN DB |
Akaza, Hideyuki Browse this author →KAKEN DB |
Ito, Toshihiro Browse this author |
Hosokawa, Hiroyuki Browse this author →KAKEN DB |
Nakayama, Toshinori Browse this author →KAKEN DB |
Harashima, Hideyoshi Browse this author →KAKEN DB |
Keywords: | Packaging |
Nanoparticle |
Delivery system |
Bladder cancer |
BCG-CWS |
Cancer immunotherapy |
Issue Date: | 28-Feb-2014 |
Publisher: | Elsevier science bv |
Journal Title: | Journal of controlled release |
Volume: | 176 |
Start Page: | 44 |
End Page: | 53 |
Publisher DOI: | 10.1016/j.jconrel.2013.12.027 |
PMID: | 24389133 |
Abstract: | The Mycobacterium bovis Bacille Calmette-Guerin cell wall skeleton (BCG-CWS) could be used to replace live BCG as a bladder cancer drug. However, because BCG-CWS is poorly soluble, has a strong-negative charge, very high molecular weight and heterogeneity in size of tens of mu m, it cannot be used in such an application. We report herein on the development of a novel packaging method that permits BCG-CWS to be encapsulated into 166 nm-sized lipid particles. The BCG-CWS encapsulated nano particle (CWS-NP) has a high uniformity and can be easily dispersed. Thus, it has the potential for use as a packaging method that would advance the scope of applications of BCG-CWS as a bladder cancer drug. In a functional evaluation, CWS-NP was efficiently taken up by mouse bladder tumor (MBT-2) cells in vitro and inhibited tumor growth in mice bearing MBT-2 tumors. Moreover, intravesically administered CWS-NP showed significant antitumor effects in a rat model with naturally developed bladder cancer. An enhancement in Th1 differentiation by CWS-NP was also confirmed in human T cells. In conclusion, CWS-NP represents a promising delivery system for BCG-CWS for clinical development as a potent bladder cancer drug. (C) 2013 Elsevier B. V. All rights reserved. |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/57253 |
Appears in Collections: | 薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|